Press Releases

KemPharm® is a clinical stage, specialty pharmaceutical company engaged in the development and discovery of proprietary prodrugs that are designed to be improved versions of widely prescribed and FDA approved products.

Press Releases

News Releases

Date Title and Summary
Toggle Summary KemPharm Enhances Pipeline with the Addition of KP879, a Potential New Treatment for Stimulant Use Disorder
KP879 is being developed with serdexmethylphenidate, KemPharm’s prodrug of d-methylphenidate, to address a critical unmet need in the treatment of problematic stimulant abuse CELEBRATION, Fla. , Nov. 13, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company
Toggle Summary KemPharm, Inc. Reports Third Quarter 2018 Results
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 4:30 p.m. ET Development Highlights: Announced positive topline results from KP415.E01 efficacy and safety trial in children with attention deficit hyperactivity disorder (ADHD) Announced positive topline results
Toggle Summary KemPharm to Report Third Quarter 2018 Results
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Thursday, November 8, 2018, 4:30 p.m. ET CORALVILLE, Iowa , Nov. 01, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary
Toggle Summary KemPharm Enters Into License Agreement with KVK Tech for the Commercialization of APADAZ®
Partnership with KVK, One of the Largest Manufacturers of Controlled Substances in the U.S., Opens the Door for Commercial Launch of APADAZ with PBMs and MCOs KemPharm to Host a Conference Call Today, Tuesday, October 30, 2018 at 4:30 p.m. ET to Discuss the Collaboration Highlights: KemPharm to
Toggle Summary KemPharm Presents Data from Intranasal and Intravenous Human Abuse Potential Trials of KP415 Prodrug at the American Academy of Child & Adolescent Psychiatry Meeting
CORALVILLE, Iowa , Oct. 24, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced the presentation of posters from two human abuse potential (HAP) trials for its KP415 prodrug
Toggle Summary KemPharm and twoXAR Announce Technology Collaboration to Develop Prodrug-Based Therapies for Multiple Indications
Drug Development Approach Combines twoXAR’s Artificial-Intelligence-Driven Drug Discovery Technology with KemPharm’s LAT TM Prodrug Technology CORALVILLE, Iowa , Oct. 23, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a clinical-stage specialty pharmaceutical company focused on the
Toggle Summary KemPharm Provides Highlights from KOL Investor Event Focused on the ADHD Treatment Landscape
Event Held Today, October 11, 2018 CORALVILLE, Iowa , Oct. 11, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today provided highlights from its investor event featuring a discussion with
Toggle Summary KemPharm Announces Pricing of Public Offering of Common Stock
CORALVILLE, Iowa , Oct. 05, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced the pricing of its underwritten public offering of 8,333,334 shares of its common stock at a price
Toggle Summary KemPharm Announces Proposed Public Offering of Common Stock
CORALVILLE, Iowa , Oct. 04, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. 
Toggle Summary KemPharm to Host KOL Investor Event Focused on the ADHD Treatment Landscape
Event to be Webcast Live on Thursday, October 11, 2018 , at 8:30 a.m. ET CORALVILLE, Iowa , Oct. 03, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that it will host an